David Thurston

Transcriptogen Ltd. operates as a drug discovery company to exploit the use of small molecules to inhibit the interaction of transcription factors (TFs) with their cognate DNA-recognition site, thus down-regulating or inhibiting the transcription of disease-related genes. The firm develops and discovers anti-cancer drugs. The company was founded by Khondaker Miraz Rahman, Paul Jackson, and Sheraz Gul and is headquartered in Bath, the United Kingdom.

Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023.

ADC Products (UK) Ltd. operates as a clinical stage biotechnology company. It develops pyrrolobenzodiazepines for antibody-drug conjugation. The company was founded in November 2000 and is headquartered in Reading, the United Kingdom.